CTOs on the Move

Averitas Pharma

www.averitaspharma.com

 
At Averitas Pharma, we strive to enable people with pain to live and feel more like their true selves. With patients at the forefront of every decision we make, we want more than to envision people not limited by their pain; we work every day with passion and determination to make it a reality. We are currently helping patients by offering the only FDA-approved, non-opioid, topical system for the treatment of neuropathic pain associated with postherpetic neuralgia (post-shingles nerve pain) and for neuropathic pain associated with diabetic peripheral neuropathy of the feet (diabetic nerve pain of the feet). We are ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Poxel

Poxel is a dynamic biopharmaceutical company that uses its extensive expertise in developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). In its mid-to-late stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities. Imeglimin, Poxel`s first-in-class lead product, targets mitochondrial dysfunction. Together, with its partner Sumitomo Dainippon Pharma, Poxel is conducting the Phase 3 Trials of IMeglimin for Efficacy and Safety (TIMES) program for the treatment of type 2 diabetes in Japan. Poxel also established a partnership with Roivant Sciences for Imeglimin`s development and commercialization in countries outside of the partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is in a Phase 2a proof-of-concept program for the treatment of NASH. PXL770 could also have the potential to treat additional metabolic diseases. PXL065 (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC) inhibitor, is in Phase 1 clinical testing and being developed for the treatment of NASH. Poxel also has additional earlier-stage programs targeting metabolic, specialty and rare diseases. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

Sapient

Sapient enables discovery of circulating biomarkers at unprecedented speed & scale, providing a deeper understanding of human biology to align patients & drug therapies.

CELLINK

CELLINK is the first bioink company revolutionizing bioprinting. Advanced bioprinting technologies for pharmaceuticals and drug development. CELLINK is pioneering cell cultivation systems through bioprinting, analysis and liquid handling or bioprocessing.

Celator Pharmaceuticals

Celator Pharmaceuticals is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ShanghaiBio Corporation

ShanghaiBio Corporation is a North Brunswick, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.